T-cell activation promotes tumorigenesis in inflammation-associated cancer

Retrovirology

Volumn 6, Issue , 2009, Pages

  Rauch, Dan ^a   Gross, Shimon ^b   Harding, John ^a   Bokhari, Sirosh ^a   Niewiesk, Stefan ^c   Lairmore, Michael ^c   Piwnica Worms, David ^a,b   Ratner, Lee ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CHEMICAL AGENT; T LYMPHOCYTE RECEPTOR; TAX PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; CARCINOGENESIS; CHRONIC INFLAMMATION; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE EXPRESSION; HEMATOPOIETIC SYSTEM TUMOR; IMAGING; IMMUNITY; LARGE GRANULAR LYMPHOCYTE LEUKEMIA; LYMPHOMA; MOUSE; NATURAL KILLER CELL; NON INVASIVE MEASUREMENT; NONHUMAN; ONCOGENE; RISK FACTOR; STIMULUS; T LYMPHOCYTE ACTIVATION; TRANSGENIC ANIMAL; WOUND; ADAPTIVE IMMUNITY; ANIMAL; EXPERIMENTAL NEOPLASM; GENETICS; HOST PATHOGEN INTERACTION; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; IMMUNOLOGY; INFLAMMATION; LYMPHOCYTE ACTIVATION; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; T CELL LEUKEMIA; T LYMPHOCYTE; VIROLOGY;

ANIMALIA; MUS;

ADAPTIVE IMMUNITY; ANIMALS; GENE PRODUCTS, TAX; HOST-PATHOGEN INTERACTIONS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; INFLAMMATION; LEUKEMIA-LYMPHOMA, ADULT T-CELL; LYMPHOCYTE ACTIVATION; MICE; NEOPLASMS, EXPERIMENTAL; NF-KAPPA B; RECEPTORS, ANTIGEN, T-CELL; RISK FACTORS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 74549150584     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-6-116     Document Type: Article

References (40)

1. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008, 454:437-444.
2. Moss SF, Blaser MJ. Inflammation and the origins of cancer. Nature Clinical Practice Oncology 2005, 2:90-97. 10.1038/ncponc0081, 16264881.
3. Schafer M, Werner S. Cancer as an overhealing wound: an old hypothesis revisited. Nature Reviews in Molecular and Cellular Biology 2008, 9:628-638.
4. Schottenfeld D, Beebe-Dimmer J. Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA Cancer Journal Clinic 2006, 56:69-83.
5. Beyer M, Schultz JL. Regulatory T cells in cancer. Blood 2006, 108:804-811. 10.1182/blood-2006-02-002774, 16861339.
6. Hsieh CS, Macatonia SE, O'Garra A, Murphy KM. T cell genetic background determines default T helper phenotype development in vitro. Journal of Experimental Medicine 1995, 181:713-721. 10.1084/jem.181.2.713, 2191880, 7836924.
7. Hsieh CS, Heimberger AB, Gold JS, O'Garra A, Murphy K. Differential regulation of T helper phenotype development by IL-4 and IL-10 in an alpha, beta-transgenic system. Proceedings of the National Academy of Sciences, USA 1992, 89:6065-6069.
8. Jin D, Zhang L, Zheng J, Zhao Y. The inflammatory Th 17 subset in immunity against self and non-self antigens. Autoimmunity 2008, 41:154-162. 10.1080/08916930701776605, 18324485.
9. Miyahara Y, Odunsi K, Chen W, Peng G, Matsuzaki J, Wang R-F. Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer. Proceedings of the National Academy of Science, USA 2008, 105:15505-15510.
10. Yu JJ, Gaffen SL. Interleukin-17: a novel inflammatory cytokine that bridges innate and adaptive immunity. Frontiers in Biosciences 2008, 13:170-177.
11. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 2001, 357:539-545. 10.1016/S0140-6736(00)04046-0, 11229684.
12. Bubici C, Papa S, Dean K, Franzoso G. Mutual cross-talk between reactive oxygen species and nuclear factor-kappa B: molecular basis and biological significance. Oncogene 2006, 25:6731-6748. 10.1038/sj.onc.1209936, 17072325.
13. Naugler WE, Karin M. NF-kB and cancer - identifying targets and mechanisms. Current Opinion in Genetics and Development 2008, 18:19-26. 10.1016/j.gde.2008.01.020, 2587362, 18440219.
14. Karin M, Lawrence T, Nizet V. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 2006, 124:823-835. 10.1016/j.cell.2006.02.016, 16497591.
15. Schulze-Luehrmann J, Ghosh S. Antigen-receptor signaling to nuclear factor kB. Immunity 2006, 25:701-715. 10.1016/j.immuni.2006.10.010, 17098202.
16. Jost PJ, Ruland J. Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood 2007, 109:2700-2707.
17. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441:431-436. 10.1038/nature04870, 16724054.
18. Grossman WJ, Kimata JT, Wong F-H, Zutter M, Ley TJ, Ratner L. Development of leukemia in mice transgenic for the tax gene of human T-cell leukemia virus type I. Proceedings of the National Academy of Sciences, USA 1995, 92:1057-1062.
19. Matsuoka M, Jeang K-T. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nature Reviews Cancer 2007, 7:270-280. 10.1038/nrc2111, 17384582.
20. Bernal-Mizrachi L, Lovly CM, Ratner L. The role of nuclear factor kB-1 and -2-mediated resistance to apoptosis in lymphomas. Proceedings of the National Academy of Science, USA 2006, 103:9220-9225.
21. Gao L, Dheng H, Zhao H, Hirbe A, Ratner L, Weilbaecher K. HTLV-1 Tax transgenic mice develop spontaneous osteolytic bone disease prevented by osteoclast inhibiton. Blood 2005, 106:4294-4302. 10.1182/blood-2005-04-1730, 1895233, 16118323.
22. Mitra-Kaushik S, Harding J, Hess J, Ratner L. Effects of the proteasome inhibitor, PS-341, on tumor growth in HTLV-1 Tax transgenic mice and Tax tumor transplants. Blood 2004, 104:802-809. 10.1182/blood-2003-11-3967, 15090453.
23. Mitra-Kaushik S, Harding J, Hess J, Schreiber R, Ratner L. Enhanced tumorigenesis in HTLV-1 Tax transgenic mice deficient in interferon gamma. Blood 2004, 104:3305-3311. 10.1182/blood-2004-01-0266, 15292059.
24. Portis T, Harding JC, Ratner L. The contribution of NF kB activity to spontaneous proliferation and resistance to apoptosis in human T-cell leukemia virus type 1 (HTLV-1) tax-induced tumors. Blood 2001, 98:1200-1208. 10.1182/blood.V98.4.1200, 11493471.
25. Rauch D, Gross S, Harding J, Niewiesk S, Lairmore M, Piwnica-Worms D, Ratner L. Imaging spontaneous tumorigenesis: inflammation precedes development of peripheral NK tumors. Blood 2009, 113:1493-1500. 10.1182/blood-2008-07-166462, 18971418.
26. Grossman W, Ratner L. Cytokine expression in human T-cell leukemia virus tax transgenic leukemia. Blood 1997, 90:783-794.
27. Gross S, Rauch D, Harding J, Heinecke JW, Ratner L, Piwnica-Worms D. Bioluminescence imaging of myeloperoxidase activity in vivo. Nature Medicine 2009, 15(4):455-61. 10.1038/nm.1886, 19305414.
28. Hanson R, Sclar G, Kanagawa O, Ley T. The 5'-flanking region of the human CGL-1/Granzyme B gene targets expression of a reporter gene to activated T-lymphocytes in transgenic mice. Journal of Biological Chemistry 1991, 266:24433-24438.
29. Alford JG, Stanley PL, Todderud G, Tramposch KM. Temporal infiltration of leukocyte subsets into mouse skin inflamed with phorbol ester. Agents Actions 1992, 37:260-267. 10.1007/BF02028118, 1338267.
30. Stanley PL, Steiner S, Havens M, Tramposch KM. Mouse skin inflammation induced by multiple topical applications of 12-O-tetradecanoylphorbol-13-acetate. Skin Pharmacology 1991, 4:262-271. 10.1159/000210960, 1789987.
31. Ganter F, Leist M, Lohse AW, Germann PG, Tiegs G. Concanavalin A-induced T-cell-mediated hepatic injury in mice: the role of tumor necrosis factor. Hepatology 1995, 21:190-198.
32. Tiegs G, Hentschel J, Wendel A. A T cell-dependent experimental liver injury in mice inducible by concanavalin A. Journal of Clinical Investigation 1992, 90:196-203. 10.1172/JCI115836, 443081, 1634608.
33. Billiau A, Matthys P. Modes of action of Freund's adjuvants in experimental models of autoimmune diseases. Journal of Leukocyte Biology 2001, 70:849-860.
34. Kaisho T, Akira S. Toll-like receptors as adjuvant receptors. Biochimica Biophysica Acta 2002, 1589:1-13.
35. Foss FM. Immunologic mechanisms of antitumor activity. Seminars in Oncology 2002, 29:5-11. 10.1053/sonc.2002.33076, 12068382.
36. Schuh AC, Keating SJ, Monteclaro FS, Vogt PK, Breitman ML. Obligatory woudning requirement for tumorigenesis in v-jun transgenic mice. Nature 1990, 346:756-760. 10.1038/346756a0, 2167455.
37. Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunology Review 2008, 222:163-179.
38. Grossman W, Ratner L. Transgenic mouse models for HTLV-1 infection. Journal of the Acquired Immune Deficiency Syndrome and Human Retroviruses 1996, 13(Suppl 1):S162-S169.
39. Hasegawa H, Sawa H, Lewis MJ, Orba Y, Sheehy N, Yamamoto Y, Ichinohe T, Tsunetsugu-Yokota Y, Katano H, Takahashi H, Matsuda J, Sata T, Kurata T, Nagashima K, Hall WW. Thymus-derived leukemia-lymphoma in mice transgenic for the Tax gene of human T-lymphotropic virus type I. Nature Medicine 2006, 12:466-472. 10.1038/nm1389, 16550188.
40. Kwon H, Ogle L, Benitez B, Bohuslav J, Montano M, Felsher DW, Greene WC. Lethal cutaneous disease in transgenic mice conditionally expressing type I human T cell leukemia virus Tax. Journal of Biological Chemistry 2005, 280:35713-35722. 10.1074/jbc.M504848200, 16105841.